The companion diagnostics market is becoming an increasingly important link between diagnosis and treatment. Instead of asking only whether a disease is present, modern healthcare is increasingly asking a more specific question: which therapy is most appropriate for this patient? That change is reshaping the role of diagnostics. A biomarker can now influence whether a targeted drug is selected, whether a patient qualifies for a therapy, or whether treatment should be adjusted as the disease evolves.

The global Companion Diagnostics Market was valued at USD 9.6 billion in 2025 and is projected to reach USD 20.1 billion by 2033, advancing at a 10.1% CAGR from 2026 to 2033. Grand View Research also identifies North America as the largest regional market, with a 39.9% revenue share in 2025, while Asia Pacific is expected to record the fastest growth over the forecast period.

Key Highlights

• Assays, kits, and reagents accounted for 59.2% of the market in 2025.
• Oncology represented 56.5% of market revenue in 2025.
• PCR held the largest technology share at 27.7%.
• Tissue samples accounted for 62.6% of the market.
• Hospitals and physician laboratories represented 38.8% of end-use revenue.

When Diagnosis Becomes Part of the Therapy

The growth of companion diagnostics is closely connected to the rise of precision medicine. Traditional treatment models often treated patients with the same disease using similar therapeutic approaches. Precision medicine changes that sequence: biomarker detection → patient selection → targeted therapy → treatment monitoring.

This relationship has particular importance in oncology, where tumors that appear similar clinically can behave very differently at the molecular level. Companion diagnostics help identify mutations, protein expression patterns, or other biomarkers that can influence therapy selection. As targeted therapies become more specialized, the diagnostic test becomes increasingly important to the overall treatment pathway rather than remaining a separate laboratory activity.

Pharmaceutical companies are therefore integrating diagnostics earlier into drug development. A therapy designed around a specific molecular target may require a validated diagnostic strategy to identify the patients most likely to benefit. This is encouraging collaborations between pharmaceutical companies, diagnostic developers, laboratories, and technology providers.

Download a free sample report or claim your copy of this full market intelligence report

Technology Is Expanding What Can Be Detected

PCR remains a major technology within the companion diagnostics market because of its sensitivity, specificity, established laboratory infrastructure, and suitability for biomarker detection. At the same time, next-generation sequencing is expanding the scope of testing by allowing multiple genes and alterations to be examined simultaneously.

The development path is increasingly moving from single biomarker testing → broader genomic profiling → integrated interpretation. NGS, digital pathology, multiplex PCR, artificial intelligence, and bioinformatics are contributing to this transition. These technologies can support the identification of complex molecular patterns and help clinicians interpret increasingly large datasets.

The regulatory landscape is evolving alongside these technologies. The U.S. Food and Drug Administration continues to maintain an expanding list of authorized companion diagnostic devices. Recent entries include additional uses of Guardant360 CDx, FoundationOne CDx, and other tests linked to specific biomarkers and therapies.

Oncology Leads, but the Opportunity Is Broader

Oncology remains the largest indication segment, and its importance reflects the close relationship between molecular biomarkers and targeted cancer therapies. Blood-based diagnostics are also opening new possibilities. Liquid biopsy can detect circulating tumor DNA and other signals without requiring a traditional tissue biopsy, creating opportunities for patients for whom tissue collection is difficult.

The role of companion diagnostics is also extending beyond oncology. Cardiovascular diseases are generating interest in biomarker-guided treatment and pharmacogenomic approaches, while other chronic and immune-related conditions create additional opportunities as targeted treatments become more sophisticated.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

A recent FDA example illustrates how treatment and testing can become tightly connected. In September 2025, the agency approved imlunestrant for certain ESR1-mutated breast cancers and simultaneously approved Guardant360 CDx as a companion diagnostic for identifying eligible patients.

The Sample Is Changing Too

Tissue continues to dominate the market, particularly for solid tumors where molecular pathology, immunohistochemistry, and related testing remain deeply established. However, blood-based testing is gaining importance because it offers a less invasive approach and may support repeated testing during treatment. This creates an important contrast in the market: tissue provides established diagnostic depth, while liquid biopsy expands accessibility and monitoring possibilities. As analytical technologies improve, the companion diagnostics industry is positioned around both approaches rather than a single testing model.

Regional Expansion Is Creating a Wider Market

North America remains the largest market because of its advanced healthcare infrastructure, research activity, pharmaceutical presence, regulatory support, and adoption of precision oncology. Europe is also building a strong environment for companion diagnostics through personalized medicine initiatives and regulatory developments surrounding in vitro diagnostics.

Asia Pacific represents another major growth opportunity. Expanding healthcare infrastructure, increasing investment in biotechnology, large patient populations, and greater awareness of precision medicine are supporting adoption. The regional opportunity also extends to countries building stronger genomic testing capabilities and clinical research ecosystems.

Key Companies

The competitive landscape includes QIAGEN, Agilent Technologies, Abbott, Thermo Fisher Scientific, F. Hoffmann-La Roche, Foundation Medicine, Myriad Genetics, Illumina, BioMérieux, Leica Biosystems, Guardant Health, and EntroGen.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Their strategies span assays, molecular testing platforms, NGS, pathology, liquid biopsy, software, and laboratory services. As drug-diagnostic co-development becomes more important, competitive differentiation is increasingly tied not only to diagnostic accuracy but also to clinical integration, regulatory capabilities, and the ability to support pharmaceutical development.

The Market’s Next Chapter

The companion diagnostics market is increasingly becoming part of the treatment infrastructure itself. The future is moving toward a model in which diagnosis, biomarker interpretation, therapeutic selection, and monitoring operate as a connected pathway. Test → interpret → match → treat → monitor is becoming a more relevant healthcare sequence.

With the global market projected to reach USD 20.1 billion by 2033, growth will depend not only on the number of diagnostic tests available, but on how effectively those tests become integrated into real clinical and drug-development decisions.